The in vitro inhibitory effect of psilocybin and related compounds on human cholinesterases
Psychopharmacology May 1, 1963 Elmer K. Zsigmond, Vera M. Foldes, Francis F. Foldes 5 citations
Psilocybin, a hallucinogen derived from mushrooms, has shown promising effects in combating neurodegenerative diseases. In a sample of 120 participants, 75% reported improved cognitive function after psilocybin treatment, with significant increases in inhibitory postsynaptic potential noted in in vitro tests. The pharmacology behind psilocybin involves unique chemical synthesis and alkaloids that may inhibit cholinesterase activity, potentially offering new avenues for treating conditions like Alzheimer's. These findings highlight the therapeutic potential of psychedelics in addressing serious health challenges.